|
Richard L. Love has 40 years of industry experience, with more than 27 years of leadership roles in the biosciences industry. He started two biopharmaceutical companies, Triton Biosciences Inc. (Alameda, CA) and ILEX Oncology Inc. (ILXO, San Antonio, TX) and served as CEO in both companies for periods of eight years each. In addition Love has served in senior executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center in San Antonio, and the Translational Genomics Research Institute (TGen) in Phoenix.
At Triton and ILEX, Love led teams that were responsible for the clinical development of four important therapeutic products that are currently in the practice of medicine: Betaseron® for patients with multiple sclerosis, Fludara® and CAMPATH® both for patients with chronic lymphocytic leukemia, and Clolar® for acute leukemias. In 2004 ILEX was acquired by Genzyme Corporation for approximately $1B.
Currently Love is a managing partner in Translational Accelerator LLC, an Arizona-based venture capital investment firm, and also serves on the Boards of PAREXEL International (PRXL), ImaRx Therapeutics (IMRX), and Molecular Profiling Institute.
| 